日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Therapeutic Anti-KIR Antibody of 1-7F9 Attenuates the Antitumor Effects of Expanded and Activated Human Primary Natural Killer Cells on In Vitro Glioblastoma-like Cells and Orthotopic Tumors Derived Therefrom

治疗性抗 KIR 抗体 1-7F9 减弱扩增和激活的人类原代自然杀伤细胞对体外胶质母细胞瘤样细胞及其衍生的原位肿瘤的抗肿瘤作用

Ryosuke Maeoka, Tsutomu Nakazawa, Ryosuke Matsuda, Takayuki Morimoto, Yoichi Shida, Shuichi Yamada, Fumihiko Nishimura, Mitsutoshi Nakamura, Ichiro Nakagawa, Young-Soo Park, Takahiro Tsujimura, Hiroyuki Nakase

Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors

体外扩增和激活的自然杀伤细胞可延长患有胶质母细胞瘤样细胞衍生肿瘤的小鼠的总体生存期

Yoichi Shida, Tsutomu Nakazawa, Ryosuke Matsuda, Takayuki Morimoto, Fumihiko Nishimura, Mitsutoshi Nakamura, Ryosuke Maeoka, Shuichi Yamada, Ichiro Nakagawa, Young-Soo Park, Motoaki Yasukawa, Takashi Tojo, Takahiro Tsujimura, Hiroyuki Nakase

Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro

体外扩增的高纯度自然杀伤细胞与替莫唑胺联合可在人胶质母细胞瘤细胞中诱导抗肿瘤作用

Yoshitaka Tanaka, Tsutomu Nakazawa, Mitsutoshi Nakamura, Fumihiko Nishimura, Ryosuke Matsuda, Koji Omoto, Yoichi Shida, Toshiharu Murakami, Ichiro Nakagawa, Yasushi Motoyama, Hiromichi Morita, Takahiro Tsujimura, Hiroyuki Nakase